Rafarma Pharmaceuticals announces the resignation of David Jones from all positions at the company

Management of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces the resignation of David Jones from all positions at the company.


Additionally Mr. Jones name was mistakenly affixed on the Annual Report and Financials for the years ending November 30, 2013 and 2014. Amended Reports and Financials for the period(s) in question have been filed in the Filings and Disclosure section of the RAFA site on the OTC Markets website using the Alternate Reporting Method.


ABOUT RAFARMA PHARMACEUTICALS, INC.:

Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.


Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,", "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

SOURCE: Rafarma Pharmaceuticals, Inc.